title: (89)Zr-labeled anti-endoglin antibody-targeted gold nanoparticles for imaging cancer: implications for future cancer therapy.
abstract: OBJECTIVE
  Antibody-labeled gold nanoparticles represent an attractive tool for cancer imaging and therapy. In this study, the anti-CD105 antibody was conjugated with gold nanoparticles (AuNPs) for the first time. The antibody biodistribution in mice before and after conjugation to AuNPs was studied, with a focus on tumor targeting.
  
  
  METHODS
  Antibodies were radiolabeled with 89Zr before conjugation to AuNPs (5 nm). Immunonanoconjugates were characterized in vitro in terms of size, stability in plasma and binding to the target. Quantitative PET imaging and ICP-MS analysis assessed in vivo distribution and specific tumor targeting of tracers.
  
  
  RESULTS
  The tumor uptake of immunoconjugates was preserved up to 24 h after injection, with high tumor contrast and selective tumor targeting. No major tracer accumulation was observed over time in nonspecific organs. ICP-MS analysis confirmed the antibody specificity after nanoparticle conjugation.
  
  
  CONCLUSIONS
  The anti-CD105 antibody conjugation to AuNPs did not greatly affect CD105-dependent tumor uptake and the efficacy of tumor targeting for cancer detection.
authors.affiliation: Biomedical Magnetic Resonance Group (REMA), Louvain Drug Research Institute, Université Catholique de Louvain, Avenue Mounier 73, 1200 Brussels, Belgium.
authors.forename: Linda
authors.initials: L
authors.lastname: Karmani
authors.forename: Virginie
authors.initials: V
authors.lastname: Bouchat
authors.forename: Caroline
authors.initials: C
authors.lastname: Bouzin
authors.forename: Philippe
authors.initials: P
authors.lastname: Levêque
authors.forename: Daniel
authors.initials: D
authors.lastname: Labar
authors.forename: Anne
authors.initials: A
authors.lastname: Bol
authors.forename: Gladys
authors.initials: G
authors.lastname: Deumer
authors.forename: Riccardo
authors.initials: R
authors.lastname: Marega
authors.forename: Davide
authors.initials: D
authors.lastname: Bonifazi
authors.forename: Vincent
authors.initials: V
authors.lastname: Haufroid
authors.forename: Carine
authors.initials: C
authors.lastname: Michiels
authors.forename: Vincent
authors.initials: V
authors.lastname: Grégoire
authors.forename: Olivier
authors.initials: O
authors.lastname: Feron
authors.forename: Stéphane
authors.initials: S
authors.lastname: Lucas
authors.forename: Thierry
authors.initials: T
authors.lastname: Vander Borght
authors.forename: Bernard
authors.initials: B
authors.lastname: Gallez
mesh_terms: D000818:Animals; D000888:Antibodies, Anti-Idiotypic; D015703:Antigens, CD / Q000737:chemistry / Q000276:immunology; D045744:Cell Line, Tumor; D003952:Diagnostic Imaging; D000071063:Endoglin; D006046:Gold / Q000008:administration & dosage; D006801:Humans; D053768:Metal Nanoparticles / Q000008:administration & dosage; D051379:Mice; D009369:Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology; D049268:Positron-Emission Tomography; D011859:Radiography; D011956:Receptors, Cell Surface / Q000737:chemistry / Q000276:immunology; D014018:Tissue Distribution; D015040:Zirconium
chemical_list: D000888:Antibodies, Anti-Idiotypic; D015703:Antigens, CD; C064206:ENG protein, human; D000071063:Endoglin; D011956:Receptors, Cell Surface; D006046:Gold; D015040:Zirconium
keywords: 89Zr; CD105; anti-endoglin antibody-targeted gold nanoparticles; biodistribution; cancer; immuno-PET; molecular imaging